Maze Therapeutics CSBO Atul Dandekar sold 6,434 shares at prices ranging from $25.81 to $27.12 per share across separate transactions. After the sales, Dandekar owned 32,316 Maze Therapeutics shares, giving investors the reported post-transaction holding for the company’s chief scientific and Business officer.
Key Highlights
- The transactions occurred between Sep. 2 and Sep. 3, 2026.
- Sale prices ranged from $25.81 to $27.12 per share.
- Atul Dandekar retained 32,316 Maze Therapeutics shares.
Maze Therapeutics, Inc. (NASDAQ: MAZE) shares sold by CSBO Atul Dandekar totaled 6,434 across separate transactions. The sales left Dandekar with 32,316 shares, establishing his reported remaining position after the transactions.
Sale Prices Spanned $25.81 to $27.12
Dandekar’s transactions took place between Sep. 2 and Sep. 3, 2026. Each transaction used the S transaction code, and the reported prices ranged from $25.81 to $27.12 per share. Maze Therapeutics identified Dandekar as its CSBO. Following the transactions, his ownership stood at 32,316 shares of Maze Therapeutics. The sales involved 6,434 Maze Therapeutics shares. The reported post-transaction balance was 32,316 shares.
FAQs
Q: How many Maze Therapeutics shares did Atul Dandekar sell?
A: Atul Dandekar sold 6,434 Maze Therapeutics shares across separate transactions. The reported sales occurred between Sep. 2 and Sep. 3, 2026.
Q: What price did Atul Dandekar receive for Maze Therapeutics shares?
A: The four reported sale transactions were executed at prices ranging from $25.81 to $27.12 per share. These transactions were reported under the S transaction code.
Q: How many Maze Therapeutics shares did Dandekar retain?
A: Following the four transactions, Atul Dandekar owned 32,316 Maze Therapeutics shares. The filing identifies Atul Dandekar as Maze Therapeutics’ CSBO.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.